221 related articles for article (PubMed ID: 33268380)
1. Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t.
Ward RJ; Pediani JD; Marsango S; Jolly R; Stoneman MR; Biener G; Handel TM; Raicu V; Milligan G
J Biol Chem; 2021; 296():100139. PubMed ID: 33268380
[TBL] [Abstract][Full Text] [Related]
2. Characterization, Dynamics, and Mechanism of CXCR4 Antagonists on a Constitutively Active Mutant.
Rosenberg EM; Harrison RES; Tsou LK; Drucker N; Humphries B; Rajasekaran D; Luker KE; Wu CH; Song JS; Wang CJ; Murphy JW; Cheng YC; Shia KS; Luker GD; Morikis D; Lolis EJ
Cell Chem Biol; 2019 May; 26(5):662-673.e7. PubMed ID: 30827936
[TBL] [Abstract][Full Text] [Related]
3. Single-Molecule Imaging Demonstrates Ligand Regulation of the Oligomeric Status of CXCR4 in Living Cells.
Lao J; He H; Wang X; Wang Z; Song Y; Yang B; Ullahkhan N; Ge B; Huang F
J Phys Chem B; 2017 Feb; 121(7):1466-1474. PubMed ID: 28118546
[TBL] [Abstract][Full Text] [Related]
4. Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.
Cox BD; Prosser AR; Katzman BM; Alcaraz AA; Liotta DC; Wilson LJ; Snyder JP
Chembiochem; 2014 Jul; 15(11):1614-20. PubMed ID: 24990206
[TBL] [Abstract][Full Text] [Related]
5. Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists.
Işbilir A; Möller J; Arimont M; Bobkov V; Perpiñá-Viciano C; Hoffmann C; Inoue A; Heukers R; de Graaf C; Smit MJ; Annibale P; Lohse MJ
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):29144-29154. PubMed ID: 33148803
[TBL] [Abstract][Full Text] [Related]
6. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.
Wu B; Chien EY; Mol CD; Fenalti G; Liu W; Katritch V; Abagyan R; Brooun A; Wells P; Bi FC; Hamel DJ; Kuhn P; Handel TM; Cherezov V; Stevens RC
Science; 2010 Nov; 330(6007):1066-71. PubMed ID: 20929726
[TBL] [Abstract][Full Text] [Related]
7. Pathway and mechanism of drug binding to chemokine receptors revealed by accelerated molecular simulations.
Pawnikar S; Miao Y
Future Med Chem; 2020 Jul; 12(13):1213-1225. PubMed ID: 32515227
[No Abstract] [Full Text] [Related]
8.
Burke BP; Miranda CS; Lee RE; Renard I; Nigam S; Clemente GS; D'Huys T; Ruest T; Domarkas J; Thompson JA; Hubin TJ; Schols D; Cawthorne CJ; Archibald SJ
J Nucl Med; 2020 Jan; 61(1):123-128. PubMed ID: 31201250
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
10. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
Gravel S; Malouf C; Boulais PE; Berchiche YA; Oishi S; Fujii N; Leduc R; Sinnett D; Heveker N
J Biol Chem; 2010 Dec; 285(49):37939-43. PubMed ID: 20956518
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor.
Rosenkilde MM; Gerlach LO; Jakobsen JS; Skerlj RT; Bridger GJ; Schwartz TW
J Biol Chem; 2004 Jan; 279(4):3033-41. PubMed ID: 14585837
[TBL] [Abstract][Full Text] [Related]
12. Single-molecule imaging reveals dimerization/oligomerization of CXCR4 on plasma membrane closely related to its function.
Ge B; Lao J; Li J; Chen Y; Song Y; Huang F
Sci Rep; 2017 Dec; 7(1):16873. PubMed ID: 29203889
[TBL] [Abstract][Full Text] [Related]
13. Carbon Dot Blinking Fingerprint Uncovers Native Membrane Receptor Organizations via Deep Learning.
Wang Q; Zhang Q; He H; Feng Z; Mao J; Hu X; Wei X; Bi S; Qin G; Wang X; Ge B; Yu D; Ren H; Huang F
Anal Chem; 2022 Mar; 94(9):3914-3921. PubMed ID: 35188385
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.
Fricker SP; Anastassov V; Cox J; Darkes MC; Grujic O; Idzan SR; Labrecque J; Lau G; Mosi RM; Nelson KL; Qin L; Santucci Z; Wong RS
Biochem Pharmacol; 2006 Aug; 72(5):588-96. PubMed ID: 16815309
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 inhibition with AMD3100 attenuates amphetamine induced locomotor activity in adolescent Long Evans male rats.
Mason B; Calhoun C; Woytowicz V; Pina L; Kanda R; Dunn C; Alves A; Donaldson ST
PLoS One; 2021; 16(3):e0247707. PubMed ID: 33647040
[TBL] [Abstract][Full Text] [Related]
17.
Alzahrani SO; McRobbie G; Khan A; D'huys T; Van Loy T; Walker AN; Renard I; Hubin TJ; Schols D; Burke BP; Archibald SJ
Dalton Trans; 2024 Mar; 53(12):5616-5623. PubMed ID: 38439632
[TBL] [Abstract][Full Text] [Related]
18. The Impact of CXCR4 Blockade on the Survival of Rat Brain Cortical Neurons.
Merino JJ; Garcimartín A; López-Oliva ME; Benedí J; González MP
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916896
[TBL] [Abstract][Full Text] [Related]
19. Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists.
Våbenø J; Haug BE; Rosenkilde MM
Future Med Chem; 2015; 7(10):1261-83. PubMed ID: 26144264
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of CXCR4 synergizes with LL-37 in the metastasis of breast cancer cells.
Pan WL; Wang Y; Hao Y; Wong JH; Chan WC; Wan DC; Ng TB
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3837-3846. PubMed ID: 30251699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
